167 related articles for article (PubMed ID: 37837424)
1. Exploring natural compound, Panicutine as leucine-rich repeat kinase 2 inhibitor against Parkinson's disease: a structure-guided approach.
Majrashi TA; Wahab S; Almoyad MAA; Alkhathami AG; Alshahrani MY
J Biomol Struct Dyn; 2023 Oct; ():1-10. PubMed ID: 37837424
[TBL] [Abstract][Full Text] [Related]
2. Virtual Screening and Biological Activity Evaluation of New Potent Inhibitors Targeting LRRK2 Kinase Domain.
Tan S; Gong X; Liu H; Yao X
ACS Chem Neurosci; 2021 Sep; 12(17):3214-3224. PubMed ID: 34387082
[TBL] [Abstract][Full Text] [Related]
3. Identification of LRRK2 Inhibitors through Computational Drug Repurposing.
Tan S; Lu R; Yao D; Wang J; Gao P; Xie G; Liu H; Yao X
ACS Chem Neurosci; 2023 Feb; 14(3):481-493. PubMed ID: 36649061
[TBL] [Abstract][Full Text] [Related]
4. Molecular dynamic investigation for Roco4 kinase inhibitor as treatment options for parkinsonism.
Dutta K; Ravi L
J Mol Model; 2024 Apr; 30(5):133. PubMed ID: 38625397
[TBL] [Abstract][Full Text] [Related]
5. Identification of chemicals to inhibit the kinase activity of leucine-rich repeat kinase 2 (LRRK2), a Parkinson's disease-associated protein.
Yun H; Heo HY; Kim HH; DooKim N; Seol W
Bioorg Med Chem Lett; 2011 May; 21(10):2953-7. PubMed ID: 21474311
[TBL] [Abstract][Full Text] [Related]
6. Structure-Based Virtual Screening and De Novo Design to Identify Submicromolar Inhibitors of G2019S Mutant of Leucine-Rich Repeat Kinase 2.
Park H; Kim T; Kim K; Jang A; Hong S
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361616
[TBL] [Abstract][Full Text] [Related]
7. Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease.
Domingos S; Duarte T; Saraiva L; Guedes RC; Moreira R
Future Med Chem; 2019 Aug; 11(15):1953-1977. PubMed ID: 31517532
[TBL] [Abstract][Full Text] [Related]
8. Molecular Modeling Study on the Interaction Mechanism between the LRRK2 G2019S Mutant and Type I Inhibitors by Integrating Molecular Dynamics Simulation, Binding Free Energy Calculations, and Pharmacophore Modeling.
Tan S; Zhang Q; Wang J; Gao P; Xie G; Liu H; Yao X
ACS Chem Neurosci; 2022 Mar; 13(5):599-612. PubMed ID: 35188741
[TBL] [Abstract][Full Text] [Related]
9. Leucine-Rich Repeat Kinase 2 in Parkinson's Disease: Updated from Pathogenesis to Potential Therapeutic Target.
Chen J; Chen Y; Pu J
Eur Neurol; 2018; 79(5-6):256-265. PubMed ID: 29705795
[TBL] [Abstract][Full Text] [Related]
10. The development of inhibitors of leucine-rich repeat kinase 2 (LRRK2) as a therapeutic strategy for Parkinson's disease: the current state of play.
Azeggagh S; Berwick DC
Br J Pharmacol; 2022 Apr; 179(8):1478-1495. PubMed ID: 34050929
[TBL] [Abstract][Full Text] [Related]
11. Recent Update on the Development of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors: A Promising Target for the Treatment of Parkinson's Disease.
Patel A; Patel S; Mehta M; Patel Y; Langaliya D; Bhalodiya S; Bambharoliya T
Med Chem; 2022; 18(7):757-771. PubMed ID: 35168510
[TBL] [Abstract][Full Text] [Related]
12. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).
Kethiri RR; Bakthavatchalam R
Expert Opin Ther Pat; 2014 Jul; 24(7):745-57. PubMed ID: 24918198
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and Preliminary Evaluation of [
Chen Z; Shao T; Gao W; Fu H; Collier TL; Rong J; Deng X; Yu Q; Zhang X; Davenport AT; Daunais JB; Wey HY; Shao Y; Josephson L; Qiu WW; Liang S
ChemMedChem; 2019 Sep; 14(17):1580-1585. PubMed ID: 31365783
[TBL] [Abstract][Full Text] [Related]
14. From a Computational Perspective: Elucidating the Neurotherapeutic and Inhibitory properties of LRRK2 Kinase Domain by a benzothiazole-based compound.
Subair TI; Soremekun OS; Olotu FA; Soliman MES
Curr Pharm Biotechnol; 2022 May; ():. PubMed ID: 35616668
[TBL] [Abstract][Full Text] [Related]
15. Neuron-autonomous susceptibility to induced synuclein aggregation is exacerbated by endogenous
MacIsaac S; Quevedo Melo T; Zhang Y; Volta M; Farrer MJ; Milnerwood AJ
Brain Commun; 2020; 2(1):fcz052. PubMed ID: 32510053
[TBL] [Abstract][Full Text] [Related]
16. Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models.
Kramer T; Lo Monte F; Göring S; Okala Amombo GM; Schmidt B
ACS Chem Neurosci; 2012 Mar; 3(3):151-60. PubMed ID: 22860184
[TBL] [Abstract][Full Text] [Related]
17. Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.
Daher JP; Abdelmotilib HA; Hu X; Volpicelli-Daley LA; Moehle MS; Fraser KB; Needle E; Chen Y; Steyn SJ; Galatsis P; Hirst WD; West AB
J Biol Chem; 2015 Aug; 290(32):19433-44. PubMed ID: 26078453
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the Role of SNCA, LRRK2, and GBA in Chinese Patients With Early-Onset Parkinson's Disease.
Chen Y; Gu X; Ou R; Zhang L; Hou Y; Liu K; Cao B; Wei Q; Li C; Song W; Zhao B; Wu Y; Cheng J; Shang H
Mov Disord; 2020 Nov; 35(11):2046-2055. PubMed ID: 32677286
[TBL] [Abstract][Full Text] [Related]
19. Integrated virtual screening and MD simulation study to discover potential inhibitors of Lyn-kinase: targeting cancer therapy.
Hassan MI; Anjum D; Mohammad T; Alam M; Khan MS; Shahwan M; Shamsi A; Yadav DK
J Biomol Struct Dyn; 2023 Dec; 41(20):10558-10568. PubMed ID: 36495308
[TBL] [Abstract][Full Text] [Related]
20. Discovering potential inhibitors of Raf proto-oncogene serine/threonine kinase 1: a virtual screening approach towards anticancer drug development.
Khan A; Bealy MA; Alharbi B; Khan S; Alharethi SH; Al-Soud WA; Mohammad T; Hassan MI; Alshammari N; Ahmed Al-Keridis L
J Biomol Struct Dyn; 2024; 42(4):1846-1857. PubMed ID: 37104027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
